‘semaglutide’ tag

Gwern Branwen

See Also
Links
Miscellaneous
Link Bibliography

[Warning: JavaScript Disabled!]

[For support of key website features (link annotation popups/popovers & transclusions, collapsible sections, backlinks, tablesorting, image zooming, sidenotes etc), you must enable JavaScript.]

Links

“Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes”, Perkovic et al 2024

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

“Estimated Sustainable Cost-Based Prices for Diabetes Medicines”, Barber et al 2024

Estimated Sustainable Cost-Based Prices for Diabetes Medicines

“Association of Semaglutide With Risk of Suicidal Ideation in a Real-World Cohort”, Wang et al 2024

Association of semaglutide with risk of suicidal ideation in a real-world cohort

“Randomized Open-Label Trial of Semaglutide and Dapagliflozin in Patients With Type 2 Diabetes of Different Pathophysiology”, Dwibedi et al 2024

Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology

“Central Glucagon-Like Peptide 1 Receptor Activation Inhibits Toll-Like Receptor Agonist-Induced Inflammation”, Wong et al 2024

Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation

“Oprah Winfrey’s Revelation about Using Weight-Loss Drugs Is a Game-Changer: Here’s Why”, Trepany 2023

Oprah Winfrey’s revelation about using weight-loss drugs is a game-changer: Here’s why

“Substantial Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series”, Richards et al 2023

Substantial Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series

“Comparative Effectiveness of Semaglutide and Tirzepatide for Weight Loss in Adults With Overweight and Obesity in the US: A Real-World Evidence Study”, Rodriguez et al 2023

Comparative Effectiveness of Semaglutide and Tirzepatide for Weight Loss in Adults with Overweight and Obesity in the US: A Real-World Evidence Study

“Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes”, Lincoff et al 2023

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

“Novo Nordisk Will Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, FLOW, Based on Interim Analysis”, Nordisk 2023

Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis

“Her Insurance Refused to Pay for Wegovy, So She Sued: Many Employers and Government Programs Won’t Cover Costly Obesity Medications. A Lawsuit Is Challenging One Such Policy”, Robbins 2023

Her Insurance Refused to Pay for Wegovy, So She Sued: Many employers and government programs won’t cover costly obesity medications. A lawsuit is challenging one such policy

“Ozempic Is Making People Buy Less Food, Walmart Says”, Case & Banjo 2023

Ozempic Is Making People Buy Less Food, Walmart Says

“Sharon Osbourne Quit Ozempic Because She’s ‘Too Skinny’”, Wickman 2023

Sharon Osbourne Quit Ozempic Because She’s ‘Too Skinny’

“A Revolution in Obesity Treatment”, Lingvay & Agarwal 2023

A revolution in obesity treatment

“What Oprah Winfrey Said about Drugs Used for Weight Loss like Ozempic, Mounjaro”, Kindelan 2023

What Oprah Winfrey said about drugs used for weight loss like Ozempic, Mounjaro

“Semaglutide in Early Type 1 Diabetes”, Dandona et al 2023

Semaglutide in Early Type 1 Diabetes

“Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults With Obesity”, Wharton et al 2023

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

“GWAS of Random Glucose in 476,326 Individuals Provide Insights into Diabetes Pathophysiology, Complications and Treatment Stratification”, Lagou et al 2023

GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification

“To Pay for Weight Loss Drugs, Some Take Second Jobs, Ring Up Credit Card Debts: Some People Pay More Than $10,000 a Year Out-Of-Pocket for Ozempic and Mounjaro”, Armour 2023

To Pay for Weight Loss Drugs, Some Take Second Jobs, Ring Up Credit Card Debts: Some people pay more than $10,000 a year out-of-pocket for Ozempic and Mounjaro

“Semaglutide and Cancer: A Systematic Review and Meta-Analysis”, Nagendra et al 2023

Semaglutide and cancer: A systematic review and meta-analysis

“US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events”, Wong et al 2023

US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events

“Novo Boosted As Trial Shows Weight-Loss Wegovy Drug Has [cardiovascular] Medical Benefits”, Fick & Skydsgaard 2023

Novo boosted as trial shows weight-loss Wegovy drug has [cardiovascular] medical benefits

“Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial: Supplement”, Jastreboff 2023

Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial: Supplement⁠:

View PDF:

/doc/longevity/glp/semaglutide/2023-jastreboff-supplement.pdf

“Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial”, Jastreboff et al 2023

Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial

“Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: a Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA”, Rosenstock et al 2023

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

“Efficacy and Safety of Once-Daily Oral Semaglutide 25 Mg and 50 Mg Compared With 14 Mg in Adults With Type 2 Diabetes (PIONEER PLUS): a Multicentre, Randomised, Phase 3b Trial”, Aroda et al 2023

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial

“Oral Semaglutide 50 Mg Taken Once per Day in Adults With Overweight or Obesity (OASIS 1): a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial”, Knop et al 2023

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

“Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2.4 Mg With Once-Weekly Semaglutide 2.4 Mg in Type 2 Diabetes: a Multicentre, Randomised, Double-Blind, Active-Controlled, Phase 2 Trial”, Frias et al 2023

Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

“A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BI 456906 in People With Overweight/Obesity”, Roux et al 2023

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BI 456906 in People with Overweight/Obesity

“Orforglipron (LY3502970), a Novel, Oral Non-Peptide Glucagon-Like Peptide-1 Receptor Agonist: A Phase 1a, Blinded, Placebo-Controlled, Randomized, Single-Dose & Multiple-Ascending-Dose Study in Healthy Participants”, Pratt et al 2023

Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single-dose & multiple-ascending-dose study in healthy participants

“People on Drugs Like Ozempic Say Their ‘Food Noise’ Has Disappeared: For Some, It’s a Startling Side Effect”, Blum 2023

People on Drugs Like Ozempic Say Their ‘Food Noise’ Has Disappeared: For some, it’s a startling side effect

“What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know”, Reynolds 2023

What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know

“I Lost 40 Pounds on Ozempic. But I’m Left With Even More Questions.”, Marcus 2023

I lost 40 pounds on Ozempic. But I’m left with even more questions.

“Novo Nordisk A/S: Oral Semaglutide 50 Mg Achieved 15.1% Weight Loss in OASIS 1 Trial”, Nordisk 2023

Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss in OASIS 1 trial

“Ozempic’s Next Act: People Taking the Drug for Weight Loss Say They Have Also Stopped Drinking, Smoking, Shopping, and Even Nail-Biting”, Zhang 2023

Ozempic’s Next Act: People taking the drug for weight loss say they have also stopped drinking, smoking, shopping, and even nail-biting

“Effects of Liraglutide on Depressive Behavior in a Mouse Depression Model and Cognition in the Probe Trial of Morris Water Maze Test”, Seo et al 2023b

Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test

“Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study”, Yammine et al 2023

Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study

“A New Drug Switched Off My Appetite. What’s Left? Mounjaro Did What Decades of Struggle With Managing Weight Couldn’t. Welcome to the Post-Hunger Age”, Ford 2023

A New Drug Switched Off My Appetite. What’s Left? Mounjaro did what decades of struggle with managing weight couldn’t. Welcome to the post-hunger age

“Why Experts Are Urging Swifter Treatment for Children With Obesity: Growing Research Has Shown That Intensive Interventions Are Needed, Scientists Say. Here Is Why Their Advice Is Changing”, Kolata 2023

Why Experts Are Urging Swifter Treatment for Children With Obesity: Growing research has shown that intensive interventions are needed, scientists say. Here is why their advice is changing

“Two-Year Effect of Semaglutide 2.4 Mg on Control of Eating in Adults With Overweight/obesity: STEP 5”, Wharton et al 2023

Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5

“Supplementary Appendix to Aroda Et Al 2032”, Anam 2023

Supplementary appendix to Aroda et al 2032

“Supplement To: Dandona P, Chaudhuri A, Ghanim H. Semaglutide in Early Type 1 Diabetes”, Ghanim 2023

Supplement to: Dandona P, Chaudhuri A, Ghanim H. Semaglutide in early type 1 diabetes⁠:

View PDF:

/doc/longevity/glp/semaglutide/2023-dandona-appendix.pdf

“Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial”, Saxena et al 2023

Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial

“Once-Weekly Semaglutide in Adolescents With Obesity”, Weghuber et al 2022

Once-Weekly Semaglutide in Adolescents with Obesity

“Liraglutide Provides Cardioprotection through the Recovery of Mitochondrial Dysfunction and Oxidative Stress in Aging Hearts”, Durak & Turan 2022

Liraglutide provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts

xKloc @ "2022-12-13"

Eli Lilly conference call summary [2022-12-13]

“Post-Bariatric Patients See More Benefits With Semaglutide vs Liraglutide—Semaglutide Users Also More Likely to Experience Weight Loss, Retrospective Study Suggests”, Dotinga 2022

Post-Bariatric Patients See More Benefits With Semaglutide vs Liraglutide—Semaglutide users also more likely to experience weight loss, retrospective study suggests

“Weight Loss TikTok Trend Triggers Shortage of Diabetic Medication”, Bui 2022

Weight loss TikTok trend triggers shortage of diabetic medication

“Dose Titration With the Glucagon-Like Peptide-1 Agonist, Liraglutide, Reduces Cue- and Drug-Induced Heroin Seeking in High Drug-Taking Rats”, Evans et al 2022

Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats

“Endpoints and Estimands: Understanding Trials of Weight-Loss Drugs”, Adler 2022

Endpoints and estimands: understanding trials of weight-loss drugs⁠:

View PDF:

/doc/longevity/glp/semaglutide/2022-adler.pdf

“Two-Year Effects of Semaglutide in Adults With Overweight or Obesity: the STEP 5 Trial”, Garvey et al 2022

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

“Hollywood’s Secret New Weight Loss Drug, Revealed: The Hype and Hazards of Ozempic”, Variety 2022

Hollywood’s Secret New Weight Loss Drug, Revealed: The Hype and Hazards of Ozempic

“Next Generation GLP-1/GIP/glucagon Triple Agonists Normalize Body Weight in Obese Mice”, Knerr et al 2022

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

“The Doctor Prescribed an Obesity Drug. Her Insurer Called It ‘Vanity.’ Many Insurance Companies Refuse to Cover New Weight Loss Drugs That Their Doctors Deem Medically Necessary.”, Kolata 2022

The Doctor Prescribed an Obesity Drug. Her Insurer Called It ‘Vanity.’ Many insurance companies refuse to cover new weight loss drugs that their doctors deem medically necessary.

“Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: the STEP 1 Trial Extension”, Wilding et al 2022

Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension

“Treatment With Glucagon-Like Peptide-1 Receptor Agonists and Incidence of Dementia: Data from Pooled Double-Blind Randomized Controlled Trials and Nationwide Disease and Prescription Registers”, Nørgaard et al 2022

Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers

“Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial”, Rubino et al 2022

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

“Exenatide Once Weekly for Alcohol Use Disorder Investigated in a Randomized, Placebo-Controlled Clinical Trial”, Klausen et al 2022

Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

“Once-Weekly Cagrilintide for Weight Management in People With Overweight and Obesity: a Multicentre, Randomized, Double-Blind, Placebo-Controlled and Active-Controlled, Dose-Finding Phase 2 Trial”, Lau et al 2021

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomized, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

“Anti-Obesity Drug Discovery: Advances and Challenges”, Müller et al 2021

Anti-obesity drug discovery: advances and challenges

“Wegovy™ Demonstrated Substantial and Sustained Weight Loss in Two-Year Study in Adults With Obesity”, Nordisk 2021

Wegovy™ demonstrated substantial and sustained weight loss in two-year study in adults with obesity

“Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials”, Overgaard et al 2021

Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials

“Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Concomitant Administration of Multiple Doses of Cagrilintide With Semaglutide 2·4 Mg for Weight Management: a Randomized, Controlled, Phase 1b Trial”, Enebo et al 2021

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomized, controlled, phase 1b trial

“Healthy Weight Loss Maintenance With Exercise, Liraglutide, or Both Combined”, Lundgren et al 2021

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

“The Gut-Brain Axis: Identifying New Therapeutic Approaches for Type 2 Diabetes, Obesity, and Related Disorders”, Richards et al 2021

The gut-brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders

“Semaglutide 2.4 Mg Once a Week in Adults With Overweight or Obesity, and Type 2 Diabetes (STEP 2): a Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial”, Davies et al 2021

Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

“Anti-Interleukin-21 Antibody and Liraglutide for the Preservation of Β-Cell Function in Adults With Recent-Onset Type 1 Diabetes: a Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial”, Herrath et al 2021

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

“Effect of Subcutaneous Semaglutide vs Placebo As an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial”, Wadden et al 2021

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial

“Once-Weekly Semaglutide in Adults With Overweight or Obesity”, Wilding et al 2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

“The Effect of Semaglutide 2.4 Mg Once Weekly on Energy Intake, Appetite, Control of Eating, and Gastric Emptying in Adults With Obesity”, Friedrichsen et al 2021

The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

“Testing the Effects of the GLP-1 Receptor Agonist Exenatide on Cocaine Self-Administration and Subjective Responses in Humans With Cocaine Use Disorder”, Angarita et al 2021

Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder

“Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes”, Albogami et al 2021

Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes

“Amylin As a Future Obesity Treatment”, Dehestani et al 2021

Amylin as a Future Obesity Treatment

“Efficacy and Safety of AM833 [cagrilintide] for Weight Loss: A Dose-Finding Trial in Adults With Overweight/Obesity [abstract]”, Lau et al 2020

Efficacy and Safety of AM833 [cagrilintide] for Weight Loss: A Dose-finding Trial in Adults With Overweight/Obesity [abstract]

“GLP-1R Agonists for the Treatment of Obesity: a Patent Review (2015–present)”, Liu et al 2020

GLP-1R agonists for the treatment of obesity: a patent review (2015–present)

“Semaglutide 2.4 Mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5”, Kushner et al 2020

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

“Activation of GLP-1 Receptors Attenuates Oxycodone Taking and Seeking without Compromising the Antinociceptive Effects of Oxycodone in Rats”, Zhang et al 2020

Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats

“Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States”, Weiss et al 2020

Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States

“Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol”, Eren-Yazicioglu et al 2020

Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol

“Management Of Endocrine Disease: Are All GLP-1 Agonists Equal in the Treatment of Type 2 Diabetes?”, Nauck & Meier 2019

Management Of Endocrine Disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

“Comparative Efficacy, Safety, and Cardiovascular Outcomes With Once-Weekly Subcutaneous Semaglutide in the Treatment of Type 2 Diabetes: Insights from the SUSTAIN 1–7 Trials”, Aroda et al 2019

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

“FDA Approves First Oral GLP-1 Treatment for Type 2 Diabetes”, FDA 2019

FDA approves first oral GLP-1 treatment for type 2 diabetes

“PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes”, Aroda et al 2019b

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

“Oral Semaglutide versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4): a Randomized, Double-Blind, Phase 3a Trial”, Pratley et al 2019

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomized, double-blind, phase 3a trial

“Glucagon-Like Peptide-1 Receptors within the Nucleus of the Solitary Tract Regulate Alcohol-Mediated Behaviors in Rodents”, Vallöf et al 2019

Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents

“The Discovery and Development of Liraglutide and Semaglutide”, Knudsen & Lau 2019

The Discovery and Development of Liraglutide and Semaglutide

“Beneficial Effects of GLP-1 Agonist in a Male With Compulsive Food-Related Behavior Associated With Autism”, Järvinen et al 2019

Beneficial Effects of GLP-1 Agonist in a Male With Compulsive Food-Related Behavior Associated With Autism

“Effects of Glucagon-Like Peptide 1 Analogs on Alcohol Intake in Alcohol-Preferring Vervet Monkeys”, Thomsen et al 2019

Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys

“Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial”, Rosenstock et al 2019

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial

“The Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Substance Use Disorder (SUD)-Related Behavioral Effects of Drugs and Alcohol: A Systematic Review”, Brunchmann et al 2019

The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioral effects of drugs and alcohol: A systematic review

“Glucagon, GLP-1 and Thermogenesis”, González-García et al 2019

Glucagon, GLP-1 and Thermogenesis

“Quantifying the Value of Orally Delivered Biologic Therapies: A Cost-Effectiveness Analysis of Oral Semaglutide”, Abramson et al 2019

Quantifying the Value of Orally Delivered Biologic Therapies: A Cost-Effectiveness Analysis of Oral Semaglutide

“Longer-Term Liraglutide Administration at the Highest Dose Approved for Obesity Increases Reward-Related Orbitofrontal Cortex Activation in Response to Food Cues: Implications for Plateauing Weight Loss in Response to Anti-Obesity Therapies”, Farr et al 2019

Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies

“Glucagon Regulation of Energy Expenditure”, Kleinert et al 2019

Glucagon Regulation of Energy Expenditure

“Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects With Type 2 Diabetes”, Granhall et al 2018

Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes

“Glucagon-Like Peptide-1 Receptor Agonists for Antipsychotic-Associated Cardio-Metabolic Risk Factors: A Systematic Review and Individual Participant Data Meta-Analysis”, Siskind et al 2018

Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis

“Efficacy and Safety of Semaglutide Compared With Liraglutide and Placebo for Weight Loss in Patients With Obesity: a Randomized, Double-Blind, Placebo and Active Controlled, Dose-Ranging, Phase 2 Trial”, O’Neil et al 2018

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomized, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

“Liraglutide for Psychiatric Disorders: Clinical Evidence and Challenges”, Camkurt et al 2018

Liraglutide for psychiatric disorders: clinical evidence and challenges

“Semaglutide versus Dulaglutide Once Weekly in Patients With Type 2 Diabetes (SUSTAIN 7): a Randomised, Open-Label, Phase 3b Trial”, Pratley et al 2018

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

“Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses With Once-Weekly Semaglutide Versus Dulaglutide in the United States”, Wilkinson et al 2018

Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States

“Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Attenuates Cocaine Seeking in Rats”, Hernandez et al 2018

Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats

“Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial”, Davies et al 2017

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial

“Effects of Liraglutide on Weight, Satiation, and Gastric Functions in Obesity: a Randomised, Placebo-Controlled Pilot Trial”, Halawi et al 2017

Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial

“Effects of Once-Weekly Semaglutide on Appetite, Energy Intake, Control of Eating, Food Preference and Body Weight in Subjects With Obesity”, Blundell et al 2017

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

“Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes”, Marso et al 2016

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

“Unimolecular Polypharmacy for Treatment of Diabetes and Obesity”, Tschöp et al 2016

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

“Neurobehavioral Effects of Liraglutide and Sitagliptin in Experimental Models”, Kamble et al 2016

Neurobehavioral effects of liraglutide and sitagliptin in experimental models

“A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes”, Nauck et al 2016

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

“Glucagon Increases Energy Expenditure Independently of Brown Adipose Tissue Activation in Humans”, Salem et al 2016

Glucagon increases energy expenditure independently of brown adipose tissue activation in humans

“Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide”, Lau et al 2015

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

“Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Prevents Development of Tolerance to Anti-Anxiety Effect of Ethanol and Withdrawal-Induced Anxiety in Rats”, Sharma et al 2014

Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats

“An Overview of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists—Available Efficacy and Safety Data and Perspectives for the Future”, Madsbad et al 2011

An overview of once-weekly glucagon-like peptide-1 receptor agonists—available efficacy and safety data and perspectives for the future

“Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4”, Kanoski et al 2011

Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4

“Society Is Fixed, Biology Is Mutable”

Society Is Fixed, Biology Is Mutable

Annotations sorted by machine learning into inferred 'tags'. This provides an alternative way to browse: instead of by date order, one can browse in topic order. The 'sorted' list has been automatically clustered into multiple sections & auto-labeled for easier browsing.

Beginning with the newest annotation, it uses the embedding of each annotation to attempt to create a list of nearest-neighbor annotations, creating a progression of topics. For more details, see the link.